What is ACADIA Pharmaceuticals Inc.'s Shariah compliance score?

ACADIA Pharmaceuticals Inc. (ACAD) has a Shariah compliance score of 68/100 (Grade: B, Acceptable) based on AAOIFI screening standards. Scores above 70 typically indicate strong compliance. The score factors in business activity screening and financial ratio analysis including debt levels, interest-bearing deposits, and prohibited income percentages. View the full breakdown at HalalScreener.app.

Does ACADIA Pharmaceuticals Inc. pass AAOIFI screening?

ACADIA Pharmaceuticals Inc. (ACAD) passes AAOIFI Shariah screening. AAOIFI requires: (1) no primary involvement in prohibited activities like alcohol, gambling, or conventional banking, (2) debt-to-market-cap below 30% (ACAD: 1.0%), (3) interest-bearing deposits below 30%, and (4) prohibited income below 5%. HalalScreener provides free AAOIFI screening for 6,200+ stocks at halalscreener.app.

How much purification is needed for ACADIA Pharmaceuticals Inc. stock?

Muslim investors purify the portion of dividends and realized gains that comes from non-permissible income by donating it to charity. HalalScreener's purification calculator at halalscreener.app/en/purification computes the exact percentage and amount for ACADIA Pharmaceuticals Inc. (ACAD) using the latest financial data.

Where can I screen ACADIA Pharmaceuticals Inc. for Shariah compliance for free?

HalalScreener (halalscreener.app) offers free Shariah compliance screening for ACADIA Pharmaceuticals Inc. (ACAD) and 5,100+ other US-listed stocks, ETFs, and 100+ cryptocurrencies. The screening uses AAOIFI Standard No. 21 and shows the verdict, compliance grade, score, and debt ratio free. No credit card or signup required for basic screening; the full ratio breakdown is part of Pro. HalalScreener also includes an AI Islamic Scholar for follow-up questions about ACAD's compliance across different madhabs (Hanafi, Shafi'i, Maliki, Hanbali, Ja'fari).

ACAD: Is ACADIA Pharmaceuticals Inc. Halal?

ACADIA Pharmaceuticals Inc.

NASDAQHealthcareUS

$26.22

-0.72%

Market Cap: 4.5B

Compliance Status

Halal

Screened on Aug 30, 2026 · AAOIFI Standard 21

Acceptable

68Score

Is ACADIA Pharmaceuticals Inc. (ACAD) halal? Halal. Based on AAOIFI screening, ACADIA Pharmaceuticals Inc. passes both qualitative (business activity) and quantitative (financial ratio) screens with a compliance score of 68/100 (Grade: B).

Quote this verdict

HalalScreener rates ACADIA Pharmaceuticals Inc. (ACAD) Halal, 68/100, grade B under AAOIFI Standard 21, screened Aug 30, 2026. Source: https://halalscreener.app/en/stock/ACAD

AvoidBorderlineClean

Business activity

What the company sells is permissible.

Passed

Company debt

Well clear of the limit

How much the company borrows, compared to its total value. AAOIFI allows up to 30%.

1.0% of 30.0% limit

What this means for you

You can own ACAD

It passes both the business activity and financial ratio screens under AAOIFI Standard 21.

Purification amount is Pro

We have screened ACAD's prohibited income, but the exact share you would need to purify is part of Pro.

About ACADIA Pharmaceuticals Inc.

ACADIA Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of central nervous system (CNS) disorders. The company's marketed product, NUPLAZID (pimavanserin), is prescribed for the management of hallucinations and delusions associated with Parkinson's disease psychosis. Beyond its commercialized offering, ACADIA maintains a robust development pipeline, featuring several promising candidates: Pimavanserin: This compound is currently undergoing Phase 3 clinical trials for additional indications, specifically for Alzheimer's disease psychosis and the negative symptoms of schizophrenia. Trofinetide: A novel synthetic compound, Trofinetide is also in Phase 3 development, aimed at treating Rett syndrome. ACP-044: This orally administered, first-in-class non-opioid analgesic is progressing through Phase 2 studies for both acute and chronic pain. ACP-319: Identified as a positive allosteric modulator of the muscarinic receptor, ACP-319 is in Phase 1 development, exploring its potential for schizophrenia and improving cognition in Alzheimer's patients. Established in 1993, ACADIA Pharmaceuticals Inc. is headquartered in San Diego, California.

Sector: Healthcare · Industry: Biotechnology

Shariah Compliance Status

AAOIFI Standard 21Updated Aug 30, 2026

Compliance History

Halalnow
since Jun 2026
Doubtful
until the change above
Not Halal
until the change above
Doubtful
until the change above

Tracked since May 2026. Updates automatically on each re-screen.

Fiscal: Q2 2026Data source: EDGAR

More Healthcare Stocks

JNJ

Johnson & Johnson

UNH

UnitedHealth Group Incorporated

ABBV

AbbVie Inc.

PFE

Pfizer Inc.

LLY

Eli Lilly and Company

A+

MRK

Merck & Co., Inc.

Free · No credit card required

Track ACAD and 6,200+ stocks with AI insights

Create your free account to unlock AI-powered compliance analysis, track your portfolio, calculate purification, and get unlimited AAOIFI screening.

Get Started Free Browse Screener

6,200+ assets AAOIFI standards Free watchlist

Frequently Asked Questions

Is ACADIA Pharmaceuticals Inc. (ACAD) halal to invest in?

Based on AAOIFI Standard 21 screening, ACADIA Pharmaceuticals Inc. (ACAD) is rated Halal with a compliance grade of B (Acceptable). It passes both the business activity screen (no primary involvement in prohibited sectors) and the quantitative financial ratio screen (debt, interest deposits, and prohibited income all below AAOIFI thresholds).

Why did ACADIA Pharmaceuticals Inc. get a B compliance rating?

ACADIA Pharmaceuticals Inc. (ACAD) received a grade of B (Acceptable) based on three AAOIFI Standard 21 financial ratios: debt-to-market-cap of 1.0% (limit 30%). The grade reflects the margin of safety across all three ratios relative to their thresholds.

What could change ACADIA Pharmaceuticals Inc.'s Shariah verdict?

ACADIA Pharmaceuticals Inc.'s verdict is re-evaluated at each annual re-screen. Three events could change it: (1) the debt-to-market-cap ratio crossing 30%, typically from new debt issuance or a major drop in share price; (2) interest-bearing deposits exceeding 30% of market cap; or (3) prohibited revenue (alcohol, gambling, conventional finance, etc.) exceeding 5% of total revenue. Verdict flips are tracked in the compliance history section above.

How often is ACADIA Pharmaceuticals Inc. re-screened for Shariah compliance?

ACADIA Pharmaceuticals Inc. (ACAD) is re-screened annually using the most recent full-year financial data from SEC filings. HalalScreener also triggers an on-demand re-screen whenever the stored data is more than 7 days old, ensuring the ratios reflect the latest available financial statements. Last screened: Aug 30, 2026.

Screened according to AAOIFI Standard No. 21 · For informational purposes only. Consult a qualified Islamic finance advisor before investing.

Disclaimer: This screening is for informational purposes only and does not constitute financial, legal, or religious advice. Compliance is evaluated using AAOIFI financial standards (debt, deposits, and prohibited income ratios) and publicly available data. Ethical, political, social, or environmental considerations are outside the scope of this screening. Individual scholars and methodologies may differ. Always consult a qualified Islamic finance advisor before making investment decisions.